Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AXL1717

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2017
2017
Abstract Background: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between… Expand
2017
2017
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2015
2015
Abstract AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2012
Review
2012
The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have become increasingly… Expand
2011
2011
Abstract Background. Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor… Expand
2011
2011
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of the new anticancer agent picropodophyllin… Expand
  • figure 1
  • table 1
  • table 4
  • figure 6
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background The incidence of lung cancer has increased… Expand
2010
2010
e13019 Background: Inhibition of the insulin-like growth factor-1 receptor (IGF-1R) has resulted in extensive antitumor effects… Expand